UDG Healthcare has announced the appointment of Mr Peter Chambre and Mr Shane Cooke as non-executive directors of the company.
Peter Chambre has held senior positions in the pharmaceutical and life sciences sectors and has been a director of a number of international public and private companies. He is also currently chairman of Immatics Biotechnologies GmbH, a clinical stage cancer immunotherapy company based in Germany and the United States, and a Trustee of Cancer Research UK since 2016.
Shane Cooke has extensive experience in the pharmaceutical and life sciences sectors in both Europe and the United States and is currently a non-executive director of NASDAQ-listed Alkermes plc, having previously held the position of president from September 2011 until his retirement in March 2018. Previously, he spent 10 years as chief financial officer of Elan Corporation plc from 2001 and from 2007 was also head of Elan Drug Technologies.
Commenting on both appointments, Peter Gray, chairman of UDG Healthcare said: “We’re delighted to welcome Peter and Shane to the board, each of whom bring extensive experience with European and US healthcare companies on both the service provision and service procurement sides. Their insights will further inform our continued strategic development of the Group. Their appointment also ensures board succession planning is well provided for in the context of recent governance guidance and our current board profile”
